Back to top
more

Zimmer Biomet (ZBH)

(Real Time Quote from BATS)

$113.26 USD

113.26
238,991

+0.62 (0.55%)

Updated Jun 6, 2024 11:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 248)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Baxter (BAX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Here's Why You Should Add Globus Medical to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.

Debanjana Dey headshot

4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus

by Debanjana Dey

Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

Zimmer (ZBH) Up 7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Urmimala Biswas headshot

3 Coronavirus-Led Threats to MedTech That May Linger

by Urmimala Biswas

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

by Zacks Equity Research

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 106.94% and 31.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?

by Zacks Equity Research

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.

Sriparna Ghosal headshot

3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis

by Sriparna Ghosal

Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.

Debanjana Dey headshot

3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest

by Debanjana Dey

Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.

Sriparna Ghosal headshot

3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs

by Sriparna Ghosal

Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.

Trina Mukherjee headshot

Medical Products Industry's Near-Term Outlook Lacks Spark

by Trina Mukherjee

AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.

Zimmer Biomet Adds New Features to mymobility with Apple Watch

by Zacks Equity Research

Zimmer Biomet (ZBH) expands mymobility digital platform by leveraging Apple's ecosystem to enhance patients' post-operative care.

The Smart Future: Will Robotics Call the Shots Post Coronavirus?

by Zacks Equity Research

Robots are assisting in surprising ways on the COVID frontline. With their pivotal role in battling the coronavirus, robotics revolution is swiftly gaining momentum and soon might be the new normal.

Zimmer (ZBH) Up 18.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sweta Killa headshot

Should iShares Morningstar MidCap Value ETF (JKI) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for JKI

Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid

by Zacks Equity Research

Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.

Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.

Zimmer Biomet (ZBH) Beats Q1 Earnings Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 22.30% and -0.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.